Effects of topical piroxicam and sun filters in actinic keratosis evolution and field cancerization: a two-center, assessor-blinded, clinical, confocal microscopy and dermoscopy evaluation trial.
Conclusion: A 6-month application of ACTX in subjects with AK lesions was associated with an improvement of AK lesion count and with a reduction in the RCM/dermoscopy severity scores of the target lesion. (Trial Registration Number: ISRCTN22070974).
PMID: 31148490 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
More News: Cancer | Cancer & Oncology | Dermatology | Diclofenac | Eyes | Melanoma | Nonmelanoma Skin Cancer | Piroxicam | Research | Skin | Skin Cancer | Study | Voltaren | Women